XTX Topco Ltd Takes Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

XTX Topco Ltd acquired a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,305 shares of the company’s stock, valued at approximately $557,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Trexquant Investment LP acquired a new stake in shares of Dr. Reddy’s Laboratories in the 4th quarter worth approximately $219,000. Orion Portfolio Solutions LLC boosted its stake in Dr. Reddy’s Laboratories by 89.1% during the 4th quarter. Orion Portfolio Solutions LLC now owns 14,532 shares of the company’s stock valued at $1,015,000 after purchasing an additional 6,846 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 6.1% during the 4th quarter. Parallel Advisors LLC now owns 6,514 shares of the company’s stock valued at $453,000 after purchasing an additional 377 shares during the period. Qtron Investments LLC raised its stake in shares of Dr. Reddy’s Laboratories by 33.6% in the 4th quarter. Qtron Investments LLC now owns 14,681 shares of the company’s stock worth $1,022,000 after buying an additional 3,690 shares in the last quarter. Finally, Schroder Investment Management Group lifted its holdings in shares of Dr. Reddy’s Laboratories by 77.6% in the fourth quarter. Schroder Investment Management Group now owns 266,653 shares of the company’s stock valued at $18,554,000 after buying an additional 116,488 shares during the period. Institutional investors own 14.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Barclays boosted their price target on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Price Performance

NYSE RDY opened at $79.36 on Tuesday. Dr. Reddy’s Laboratories Limited has a 1 year low of $63.72 and a 1 year high of $84.46. The business’s fifty day moving average is $81.14 and its two-hundred day moving average is $75.74. The stock has a market capitalization of $13.24 billion, a P/E ratio of 19.69, a P/E/G ratio of 1.74 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.10). The company had revenue of $919.80 million for the quarter, compared to analysts’ expectations of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. On average, research analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.